Pressure Mounts For Roche On PD-L1 Strategy
This article was originally published in The Pink Sheet Daily
Roche spent much of its first quarter conference call answering questions about its PD-L1 antibody strategy, particularly if the drug might be ready for regulatory filing in 2015, earlier than expected, and how it will compete effectively following on the heels of two competitors.
You may also be interested in...
Studies presented at AACR highlight pros and cons of two new potential, competing frontline regimens in melanoma – Keytruda alone instead of Yervoy, or Yervoy in combination with Opdivo.
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.